Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings results on Monday. The biotechnology company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.09 by $0.15, Zacks reports. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The company had revenue of $122.06 million for the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals updated its FY 2025 guidance to EPS.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock traded up $0.14 during trading hours on Wednesday, hitting $3.03. The company had a trading volume of 1,084,427 shares, compared to its average volume of 2,554,336. The firm has a market capitalization of $491.85 million, a price-to-earnings ratio of -60.49 and a beta of 0.37. The firm’s fifty day moving average is $1.54 and its 200 day moving average is $1.07. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.13.

Wall Street Analyst Weigh In

Several research analysts recently commented on IRWD shares. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Wells Fargo & Company lifted their price objective on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.34.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Captrust Financial Advisors acquired a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth approximately $32,000. Engineers Gate Manager LP boosted its stake in Ironwood Pharmaceuticals by 369.2% in the second quarter. Engineers Gate Manager LP now owns 73,354 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 57,720 shares in the last quarter. Bridgeway Capital Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 141.9% during the second quarter. Bridgeway Capital Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 44,000 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Ironwood Pharmaceuticals during the 1st quarter worth about $57,000. Finally, Strs Ohio acquired a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at about $113,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.